Conversion chemoradiotherapy combined with nab-paclitaxel plus cisplatin in patients with locally advanced borderline-resectable or unresectable esophageal squamous cell carcinoma: a phase i/ii prospective cohort study
Authors
Qingfeng Zheng
Jianyang Wang (ORCID: https://orcid.org/0000-0001-9263-8914)
Beijing Xisike Clinical Oncology Research Foundation
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Conversion chemoradiotherapy combined with nab-paclitaxel plus cisplatin in patients with locally advanced borderline-resectable or unresectable esophageal squamous cell carcinoma: a phase i/ii prospective cohort study
Qingfeng Zheng, Jianyang Wang, Zefen Xiao, Xin Wang et al.
Citations
5 citations
Journal
Strahlentherapie und Onkologie
Topics
Esophageal Cancer Research and Treatment
Field-Weighted Citation Impact (FWCI)
2.86
article
Conversion chemoradiotherapy combined with nab-paclitaxel plus cisplatin in patients with locally advanced borderline-resectable or unresectable esophageal squamous cell carcinoma: a phase i/ii prospective cohort study
Qingfeng Zheng, Jianyang Wang, Zefen Xiao, Xin Wang, Xiankai Chen, Qinfu Feng, Wenyang Liu, Jima Lv, Zongmei Zhou, Jiao Li, Lei Deng, Xiaozheng Kang, Nan Bi, Yong Li, Wenqing Wang, Tao Zhang, Zhen Wang, Yin Li, Guojie Feng, Nuo Yu, Jianjun Qin, Ruixiang Zhang
article en
5 citations
Abstract
No abstract available for this paper.
Publication Tag
Strahlentherapie und OnkologieVol. 200(12)
Institutions
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), National Cancer Center (US)
Funders
Beijing Xisike Clinical Oncology Research Foundation